Lamivudine Teva Pharma B.V

Lamivudine, the active ingredient in Lamivudine Teva Pharma B.V., is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It is used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adults and children.

GNH USA supplies Lamivudine Teva Pharma B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global treatment needs. Our distribution network ensures timely delivery across continents.

Lamivudine is indicated for viral infections that involve reverse transcriptase activity, primarily within the HIV and hepatitis B disease families.

- HIV infection: reduces viral load and helps restore immune function in infected individuals. - Chronic hepatitis B infection: suppresses viral replication and improves liver function markers. - Prevention of mother‑to‑child transmission of HIV: used with other antiretrovirals during pregnancy to lower the risk of neonatal infection.

Lamivudine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Pancreatitis - Stevens‑Johnson syndrome - Severe hypersensitivity reactions

When prescribing lamivudine, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - Pregnancy and lactation: weigh benefits against potential risks; consult specialist. - Concomitant antiretroviral therapy: avoid overlapping toxicities. - Resistance testing: perform before initiating therapy to ensure susceptibility. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Lamivudine interacts with several agents; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Zidovudine: additive bone marrow suppression. - Co‑administration with other nucleoside analogues that cause mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., tenofovir): monitor renal function. - Protease inhibitors (e.g., ritonavir): may increase lamivudine levels. - Anticoagulants (e.g., warfarin): monitor INR.